Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04602468
PHASE4

Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

Sponsor: Royal College of Surgeons, Ireland

View on ClinicalTrials.gov

Summary

RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) triple combination therapy in people with cystic fibrosis initially over a two year period, followed by a five year extension period. Measured outcomes include measures of lung function, lung inflammation, lung imaging, abdominal symptoms, gut inflammation, liver function, pancreatic exocrine function, nasal inflammation, quality of life and adherence to therapy. The study will examine outcomes in two cohorts, children aged six to eleven years and children and adults aged twelve and above.

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

206

Start Date

2020-09-03

Completion Date

2029-07-01

Last Updated

2026-09-09

Healthy Volunteers

No

Interventions

DRUG

Elexacaftor/Tezacaftor/Ivacaftor

The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.

Locations (7)

Children's Health Ireland at Crumlin

Dublin, Leinster, Ireland

University Hospital Limerick

Limerick, Limerick, Ireland

Children's Health Ireland at Temple Street

Dublin, Ireland

St. Vincent's University Hospital

Dublin, Ireland

Children's Health Ireland at Tallaght

Tallaght, Ireland

Royal Belfast Hospital for Sick Children

Belfast, United Kingdom

Royal Brompton Hospital

London, United Kingdom